Business
MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…
By David Bautz, PhD NASDAQ:MTVA READ THE FULL MTVA RESEARCH REPORT Business Update DA-1241 in Combination with Efruxifermin Shows Enhanced Hepatoprotective Effects On June 21, 2025, MetaVia Inc. (NASDAQ:MTVA) announced the presentation of preclinical data for DA-1241, the company’s novel G-protein Coupled Receptor 119 (GPR119) agonist, in combination with efruxifermin, a fibroblast growth factor
About this update from Metavia Inc.
[{"type":"text","content":"By David Bautz, PhD","length":19,"tagName":"p"},{"type":"text","content":"NASDAQ:MTVA","length":11,"tagName":"p"},{"type":"text","content":"READ THE FULL MTVA RESEARCH REPORT","length":34,"tagName":"p"},{"type":"text","content":"Business Update","length":15,"tagName":"p"},{"type":"text","content":"DA-1241 in Combination with Efruxifermin Shows Enhanced Hepatoprotective Effects","length":80,"tagName":"p"},{"type":"text","content":"On June 21, 2025, MetaVia Inc. (NASDAQ:MTVA) announced the presentation of preclinical data for DA-1241, the company’s novel G-protein Coupled Receptor 119 (GPR119) agonist, in combination with efruxifermin, a fibroblast growth factor 21 (FGF21) analogue, in a metabolic dysfunction-associated steatohepatitis (MASH) mouse model. The data was presented in a poster session at the 85th American Diabetes Association Scientific Sessions. A copy of the presentation can be found here.","length":481,"tagName":"p"},{"type":"text","content":"The study utilized mice fed the Gubra Amylin NASH (GAN) diet for 36 weeks. The GAN diet induces metabolic and histopathologic hallmarks of fibrotic NASH (Veidal et al., 2019). Mice were then randomized to receive either placebo, DA-1241 (100 mg/kg once daily, oral), efruxifermin (EFX, 1mg/kg once weekly, subcutaneous), or the combination therapy for 12 weeks. An outline of the study is given below.","length":401,"tagName":"p"},{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","className":"","disableSlideshowImg":false,"size":{"original":{"width":1324,"height":714,"url":"https://media.zenfs.com/en/scr.zacks.com/f891cfb7d72d499a078026f7d14e7d9c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/d.IucyNSUwbgxtQb7dFrqA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTUxODtjZj13ZWJw/https://media.zenfs.com/en/scr.zacks.com/f891cfb7d72d499a078026f7d14e7d9c","width":960,"height":518},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/NhS72rSNTwUaAd86vDK_8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMjk0O2NmPXdlYnA-/https://media.zenfs.com/en/scr.zacks.com/f891cfb7d72d499a078026f7d14e7d9c","width":1200,"height":647}}},{"type":"text","content":"The following image shows the change in NAFLD Activity Score (NAS) following 12 weeks of treatment. The combination therapy showed a significant improvement in NAS compared to the MASH control group. In addition, enhanced activity was no...